en Molecular Immunology & Vaccines Molecular Immunology & Vaccines مقاله کامل Full Length/Original Article <span style="font-size:11px;"><span style="line-height:normal"><span calibri=""><b><span style="color:black">Background:</span></b> Identification of specific antigens is highly beneficial for early detection, diagnosis, staging, and outcome prediction of cancer. This study aimed to evaluate the expression and prognostic value of CD56 (140 kDa isoform) in <span style="color:black">invasive ductal carcinoma</span> (IDC). </span></span><br> <span style="line-height:normal"><span calibri=""><b><span style="color:black">Methods: </span></b>Sixty-five patients with IDC who underwent radical surgery or mastectomy as the primary treatment were included. Proper formalin-fixed and paraffin embedded tissue blocks of the patients were prepared and stained by IHC for CD56 (140 kDa isoform) molecule. Chi-square and fisher exact tests were used to compare the results against the clinicopathologic data of patients. Kaplan-Meier and log-rank test were employed to study the prognostic value of the target antigen. </span></span><br> <span style="line-height:normal"><span calibri=""><b><span style="color:black">Results:</span></b> The expression pattern of CD56 was granular and cytoplasmic. There were significant associations between the intensity of CD56 expression in invasive cells and carcinoma <i>in situ</i> (<i>p</i> = 0.005) and normal ducts (<i>p</i> = 0.010). Among all clinicipathologic parameters, there was only a significant association between the expression of <span style="color:black">estrogen receptor</span> (ER) and CD56 (<i>p</i> = 0.023). Neither OS (<span style="color:black">overall survival</span><i>; p</i> = 0.356) nor DFS (<span style="color:black">disease-free survival</span><i>; p</i> = 0.976) had significant correlation with CD56 expression. </span></span><br> <b><span style="line-height:115%"><span calibri=""><span style="color:black">Conclusion:</span></span></span></b> <span style="line-height:115%"><span calibri="">Our data indicated that the CD56 marker offers no prognostic value in terms of predicting the OS or DFS for up to eight years after primary surgery. Furthermore, the intensity of its expression is similar between normal, non-invasive, and invasive cells. Considering the generally better outcome of ER+ BC patients than their ER-counterparts, the CD56 marker may be indirectly associated with a more favorable prognosis among IDC patients.</span></span></span> Breast cancer, Neural cell adhesion molecule, Prognosis 175 182 http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-4658-1&slc_lang=en&sid=1 Kianoush Niknam ghaderia@sums.ac.ir 0000-0003-0849-3375 No Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Akbar Safaei safaeia@sums.ac.ir 0000-0002-2542-9861 No Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Abbas Ghaderi kianoushN.1994@gmail.com 0000-0002-3506-0463 Yes Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran